Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 228.71 USD -0.66% Market Closed
Market Cap: 404.2B USD

Intrinsic Value

The intrinsic value of one ABBV stock under the Base Case scenario is 205.47 USD. Compared to the current market price of 228.71 USD, Abbvie Inc is Overvalued by 10%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABBV Intrinsic Value
205.47 USD
Overvaluation 10%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Abbvie Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ABBV?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ABBV valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Abbvie Inc.

Explain Valuation
Compare ABBV to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

With Humira’s patent protection expiring in key markets, AbbVie faces an impending revenue cliff that may be difficult to replace with newer therapies in the short term, potentially straining cash flows and earnings.

AbbVie’s heavy reliance on the immunology franchise means that any pipeline setbacks—especially for Skyrizi or Rinvoq—could undercut management’s guidance for replacing lost Humira sales, exposing the firm to volatility.

The large debt load from recent acquisitions, combined with integration risks from Allergan, may limit AbbVie’s flexibility to pursue additional M&A deals or invest aggressively in R&D, weakening its competitive stance.

Bull Theses

Skyrizi and Rinvoq have shown strong clinical data and commercial traction, signifying AbbVie’s potential to sustain leadership in immunology and mitigate the Humira patent cliff through these next-generation therapies.

The Allergan acquisition diversifies AbbVie’s product portfolio into aesthetics and neuroscience, mitigating overdependence on immunology and providing additional long-term growth and cash flow opportunities.

AbbVie’s robust R&D engine and track record of successful drug development, paired with strategic partnerships, position it to expand its oncology and neuroscience pipelines, potentially unlocking future blockbusters beyond its immunology foundation.

Show More Less
How do you feel about ABBV?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abbvie Inc

Current Assets 28.5B
Cash & Short-Term Investments 5.7B
Receivables 12.8B
Other Current Assets 10.1B
Non-Current Assets 105.4B
Long-Term Investments 291m
PP&E 5.5B
Intangibles 89.9B
Other Non-Current Assets 9.6B
Current Liabilities 39.4B
Accounts Payable 33.6B
Short-Term Debt 3.8B
Other Current Liabilities 2B
Non-Current Liabilities 97.1B
Long-Term Debt 63B
Other Non-Current Liabilities 34.2B
Efficiency

Free Cash Flow Analysis
Abbvie Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Abbvie Inc

Revenue
59.6B USD
Cost of Revenue
-17.2B USD
Gross Profit
42.4B USD
Operating Expenses
-22.7B USD
Operating Income
19.7B USD
Other Expenses
-17.4B USD
Net Income
2.3B USD
Fundamental Scores

ABBV Profitability Score
Profitability Due Diligence

Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
Exceptional ROIC
ROE is Increasing
72/100
Profitability
Score

Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

ABBV Solvency Score
Solvency Due Diligence

Abbvie Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Average Altman Z-Score
Long-Term Solvency
Short-Term Solvency
43/100
Solvency
Score

Abbvie Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 248.59 USD with a low forecast of 189.52 USD and a high forecast of 303.45 USD.

Lowest
Price Target
189.52 USD
17% Downside
Average
Price Target
248.59 USD
9% Upside
Highest
Price Target
303.45 USD
33% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Dec 5, 2025
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for ABBV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ABBV Insider Trading
Buy and sell transactions by insiders

ABBV News

Other Videos
What is the Intrinsic Value of one ABBV stock?

The intrinsic value of one ABBV stock under the Base Case scenario is 205.47 USD.

Is ABBV stock undervalued or overvalued?

Compared to the current market price of 228.71 USD, Abbvie Inc is Overvalued by 10%.

Back to Top